Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 2,301–2,400 of 3,704
Perceptions and stigma of anti-obesity pharmacotherapy in adult Polish women
Witaszek, T., Kłoda, K., Mastalerz-Migas, A., & Babicki, M. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1687120 · Cited by 1
Fu, L., Fan, J., Zhong, J., Xie, X., Yang, S., & Yue, X. (2026) · Clinical Medicine Frontiers · doi:10.57237/j.cmf.2026.01.001 · Cited by 1
Younis, A., Henney, A. E., Riley, D. R. J., Anson, M., Zhao, S. S., Hernández, G., Malik, R. A., Su, L., Lip, G. Y. H., Cuthbertson, D. J., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113083 · Cited by 4
Übergewicht und Adipositas – Konventionelle Therapien
Panhofer, P., & Rothe, S. (2026) · Springer eBooks · doi:10.1007/978-3-662-68171-8_25 · Cited by 1
Soepnel, L. M., Conradie, C. M., Geffen, H., Choo-Kang, C., Bovet, P., Viswanathan, B., Bedu-Addo, K., Boateng, P. O., Dei, O. A., Apusiga, K., et al. (2026) · BMJ Public Health · doi:10.1136/bmjph-2025-003427 · Cited by 2
Endocrines: A Passion for Endocrinology, Five Years on
Brunetti, A. (2026) · Endocrines · doi:10.3390/endocrines7010003 · Cited by 1
Development of the Weight and Emotions Scale (WES)
Kanu, C., Kimel, M., GOETZ, I. A., Neff, L. M., Boye, K. S., Stefan, M., & Jordan, J. B. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70119 · Cited by 1
A New Era in the Medical Management of Obesity
Porterfield, F., Fatima, A., Boaventura, B. C. B., Madhar, A., Srivastava, G., & Stanford, F. C. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-125437 · Cited by 3
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Epicardial adipose tissue in coronary microvascular disease
Gašpárková, V., Tran, B. T., Ošťádal, P., Lambert, L., Hájek, P., & Kala, P. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100734 · Cited by 11
Ishigaki, Y., Yamada, M., Shingaki, T., Oura, T., & Shimomura, I. (2026) · Obesity · doi:10.1002/oby.70131 · Cited by 2
Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss
Sterckx, M., & de Keyser, L. F. M. (2026) · Cureus · doi:10.7759/cureus.102627 · Cited by 1
Черкашин, Д. В. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-551 · Cited by 1
A Shift from Diabetic Clinical Therapy to Aesthetic Use: The Ozempic Phenomenon
Sibarani, N. T., Simanjuntak, A. A., Simanjuntak, D. M. P., Tuba, S., Priyono, A., Sumaryono, B., & Sari, E. P. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.142019 · Cited by 1
Chen, Q., Chen, T., Lin, W., & Chen, X. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s585436 · Cited by 3
Prado, B. S., Mazzotti, D. R., Franci, A., Baracioli, L., Barbado, K. R., Saretta, R., Filho, R. K., & Drager, L. F. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoaf071 · Cited by 1
Bredum, S. K., Jacobsen, J. M., Halling, J. F., Blom, I., Lewis, C. T. A., Ochala, J., Fredholm, M., Lundh, S. H., Schmücker, M., Ozenne, B., et al. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00480.2024 · Cited by 2
Zhang, F., Chen, W., Wang, H., Wu, D., Chen, Z., Cheng, R., Hu, J., Xie, L., Qiu, Y., Zhou, Z., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.02.006 · Cited by 3
Beyond the prescription: A holistic GP approach to obesity and weight loss medications
Tyler, B. (2026) · InnovAiT Education and inspiration for general practice · doi:10.1177/17557380261420769 · Cited by 1
Mushtaq, M. N., Hamid, M., Rahman, A., Javed, F., Issa, M. T., Naqvi, M., Kabir, S. A., Mirza, S., Khan, A. U., & Karim, M. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08525-4 · Cited by 1
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
Uhrenholt, N. G., Ganeshalingam, A. A., Arnfred, S., Gæde, P., Pedersen, A. K., Larsen, P. V., Frystyk, J., & Bilenberg, N. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.02.009 · Cited by 4
Rahul, C., Nobbenhuis, M., Heath, O. M., Hacking, M. B., Self, R., Lo, Q., & Ind, T. E. J. (2026) · Journal of Robotic Surgery · doi:10.1007/s11701-026-03219-6 · Cited by 1
Chan, Z. H., Omar, A. S., Gill, K., Volucke, G., Azhar, M. M., Haleem, S. M., Sia, J. E., Rahman, O. U., Ahmad, M., Shahid, N., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001209 · Cited by 2
Selvan, N. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20260443 · Cited by 1
Jayathilaka, N. S., Wijekoon, K. J., Sachinthani, S. D. D., Weththasinghe, A. V., Ganamurali, N., & Sabarathinam, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01887-7 · Cited by 2
Cardiovascular Science, Medicine, and Society: The Brave New World
Regan, J. A., Laitner, M. H., & Dzau, V. J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.085 · Cited by 3
Vitreous hemorrhage in a patient on tirzepatide: Coincidence or drug induced?
Azeem, S., Bulushi, L. A., & Sabt, B. (2026) · Oman Journal of Ophthalmology · doi:10.4103/ojo.ojo_437_25 · Cited by 2
Mondoh, A., Contreras, F., Craig, H. C., Crotty, M., & le Roux, C. W. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100256 · Cited by 3
Medeiros, S. G. F., Guimarães, R. D. C. A., Inada, A. C., Fernandes, C. D. P., Ferreira, R. D. S., Freitas, K. D. C., Donadon, J. R., do Nascimento, V. A., & Hiane, P. A. (2026) · Antioxidants · doi:10.3390/antiox15030322 · Cited by 2
The emerging implications of GLP-1 receptor agonists in radiation therapy
Reinicke, T., & Dilworth, J. T. (2026) · The Oncologist · doi:10.1093/oncolo/oyag073 · Cited by 1
COHEN, R. V., Ponce, J., Dayyeh, B. K. A., Stier, C. K., Levinson, R. S., Salminen, P. T. P., & Prager, G. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08518-3 · Cited by 2
Sarcopenia in the era of GLP-1 receptor agonists: Implications for the internist
Shaooli, R. C. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.02.034 · Cited by 3
GLP ‐1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation
Hurtado, R. L., Amato, A. A., Corrêa, H. D. L., & Silveira, D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70609 · Cited by 5
Pharmacological therapy in the obese patient: is it only a matter of fat loss?
Borghi, C., & Bragagni, A. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag029 · Cited by 1
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Farkas, G. J., Solinsky, R. J., & Park, A. (2026) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2026.02.498 · Cited by 1
Joongpan, W., Boonmuen, N., Sinchai, P., Lapmanee, S., Klamsakul, N., & Pathomthongtaweechai, N. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70232 · Cited by 3
Nicoletti, C. F., Lara, F. V.-O. D., & Martinez, J. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100690 · Cited by 2
Antza, C., Jordan, J., McGowan, B. M., Ciudin, A., Filippi-Arriaga, F., Hönemann, J., Jelacovic, A., Nilsson, P. M., Tsioufis, K. P., Doehner, W., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004285 · Cited by 1
Song, S., Hyeon, M., Kim, S., Kang, Y., Hahm, S., Park, E. W., Shin, B. S., & Shin, S. (2026) · Journal of Analytical Science & Technology · doi:10.1186/s40543-026-00540-5 · Cited by 1
GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits
Province, H. S., Hayes, N. W., Leong, N. A., Tang, E., Lorch, C. M., Pekerman, A., Xia, J. L., & Beutler, L. R. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117116 · Cited by 3
Mortada, I., Lee, A. W., Quach, V., Rice, J. C., Mansour, S., Chatila, K., Shalaby, M., Blackwell, T. A., & Jneid, H. M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.020 · Cited by 1
GLP-1-derived therapies and risk of sarcopenia: myth or reality?
Scheen, A. J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2640980 · Cited by 5
Viral medicine: social media and new expectations of obesity treatment
Tejera-Perez, C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00069-0 · Cited by 1
Eiswirth, E., & Salib-Barrios, M. (2026) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2026.105766 · Cited by 1
Geagea, M., Kozaily, E., Buchanan, C. J., Litwin, S. E., & Tedford, R. J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10601-x · Cited by 1
Boulmpou, A., Pană, M.-A., İleri, Ç., Ullah, I., Cacciatore, S., Spadafora, L., Bernardi, M., Busnatu, Ș., Biondi‐Zoccai, G., & Perone, F. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag022 · Cited by 2
de Velasco, L. M. C., Flores, J. E. G., Kraus-Fischer, G., Arteaga, J. L. M., Casas, M. J. O., Nava, K. N. A., & Morales, F. M. M. (2026) · Cureus · doi:10.7759/cureus.105734 · Cited by 4
Mazzeo, A., Alaimo, V., & Grimaldi, L. M. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08977-7 · Cited by 2
Caponio, D., & Acucella, G. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100696 · Cited by 2
WHO Guideline on GLP-1 Therapies for Treatment of Obesity in Adults
Dellepiane, D., Fadda, M., & Mercado, D. O. (2026) · JAMA · doi:10.1001/jama.2026.0684 · Cited by 1
Benny, O., Agarwal, A., Alecock, H., Subramani, R. G., Pawar, A., Shams, Z., Kermansaravi, M., Pouwels, S., Yang, W., Gerald, C., et al. (2026) · Pancreatology · doi:10.1016/j.pan.2026.03.021 · Cited by 6
Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide
Barenbaum, S. R., Gonzalez, A., Verzani, Z., Zhao, A. S., & Shukla, A. P. (2026) · Obesity · doi:10.1002/oby.70179 · Cited by 3
Sanyal, A. J., Abdelmalek, M. F., & Loomba, R. S. (2026) · Hepatology · doi:10.1097/hep.0000000000001734 · Cited by 1
Gouda, P., Allyn, N., Belin, R. M., Borentain, M., Butler, J., Curtis, L. H., George, J. T., Hornik, C. P. V., Jackman, J. G., Jessup, M. L., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102713 · Cited by 2
Self-citationEdens, E. S., Falise, H., Smith, R., & Bernardo, E. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70140 · Cited by 2
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040447 · Cited by 1
GLP-1 medications for weight-loss: a triumph of marketing over patient care
Chastain, R., Meadows, A., & Adams, L. (2026) · Fat Studies · doi:10.1080/21604851.2026.2646492 · Cited by 6
Tsutsumi, T., Tang, N. S. Y., Ng, C. H., Suzuki, H., Syn, N. L., Sasikumar, N. A., Ho, G. J. K., Chua, D., Tioh, J. K., Pramotedham, T., et al. (2026) · Med · doi:10.1016/j.medj.2026.101077 · Cited by 3
State of the art and novel treatments in psoriatic arthritis
Hackett, S., Al‐Mossawi, H., & Coates, L. C. (2026) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2026.102135 · Cited by 1
Ji, L., Gao, L., Dong, R., Yuan, M., Zhao, D., Pang, S., Zhao, J., Zhao, L., & Chen, W. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102743 · Cited by 2
Self-reported side effects of semaglutide and tirzepatide in online communities
Sehgal, N. K. R., Tronieri, J. S., Ungar, L., & Guntuku, S. C. (2026) · Nature Health · doi:10.1038/s44360-026-00108-y · Cited by 11
Mahmod, M., Dennis, A., Lian, J., Langford, C., Rahimi, K., & Wamil, M. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10629-z · Cited by 2
Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes
Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01865-5 · Cited by 2
Adamidis, N., Margariti, T., Georgakopoulou, V., Adamidi, S., Desalermos, A. P., Kyventidou, M., Koutrakos, T., Bouros, D. E., Papadopoulou, N., & Adamidis, S. (2026) · Cureus · doi:10.7759/cureus.107081 · Cited by 3
Mitropoulou, P., Prokšelj, K., Janež, A., Gil, F. R., Verma, S., Jurić, I., Vida, V. L., Gatzoulis, M. Α., & Brida, M. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag067 · Cited by 3
Beyond Weight Loss: Preserving Muscle in the Era of Incretin Therapy
Suetta, C. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-01172 · Cited by 2
Zhong, Q., Xiong, Y., Zhu, Y., Ouyang, Q., Chen, X., Qin, F., Xu, F., An, K., Yu, B., & Qin, M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114940 · Cited by 3
Galindo, R. J., Aronne, L. J., Horn, D. B., Miras, A. D., Dunn, J. P., Cao, D., Lee, C. J., Karanikas, C. A., Heine, R. J., Falcón, B. L., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02895-3 · Cited by 3
Self-citationObesity management medications for the surgeon
Harris, M., Mahdi, S., Fairfield, C. J., Brown, L. R., Wadley, M., & Miras, A. D. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103307 · Cited by 1
Beyond GLP1: modulating multiple nutrient-stimulated hormone pathways to reduce cardiovascular risk
Kang, Y. M., Harrington, J., Aroda, V. R., & McGuire, D. K. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01296-6 · Cited by 1
Exercise as a Metabolic Therapy for MASLD: Beyond Weight Loss Toward Sustainable Exercise Strategies
Roh, H., & Bae, J. Y. (2026) · Medicina · doi:10.3390/medicina62040784 · Cited by 1
Alati, A., Scher, N., & Tolédano, A. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10691-1 · Cited by 3
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 3
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Ahmed, E. O., Gasmallah, S. I., Jalal, M., Ahmed, W. R., & Fadul, K. H. (2026) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580261441498 · Cited by 2
Eisa, N., & Barood, O. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.04.014 · Cited by 3
The Obesity–OSA–Arrhythmia Axis: Pathophysiological Mechanisms and Translational Therapeutic Targets
Cacciapuoti, F., Caso, I., Buonomo, A., Crispo, S., Taglialatela, V., Carpinella, G., Volpicelli, M., & Mauro, C. (2026) · Life · doi:10.3390/life16050737 · Cited by 2
Brown, W. A., Sumithran, P., Cowley, M. A., Cohen, R., le Roux, C. W., Schauer, P. R., Agarwal, S., Ard, J., Boza, C., Cargiuolo, J. L., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08692-4 · Cited by 1
Al‐Ozairi, E., Al-Awadi, A. A., Taghadom, E., Kandari, J. A., Alsaeed, D., ALGHANIM, S., Mashankar, A., & le Roux, C. W. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-117431 · Cited by 1
The cardiometabolic triad: obesity, sleep-disordered breathing, and epicardial adipose tissue
Cacciapuoti, F., Carpinella, G., Sessa, F., Liguori, M., Casolaro, F., Russo, M., Verde, N., & Mauro, C. (2026) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.26.07120-6 · Cited by 1
Obesity and respiratory diseases: mechanisms, phenotypes, and clinical implications
Soliman, A. M., Abouzeid, A., & Ahmed, H. H. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02164-6 · Cited by 3
Gilbert, S. J., Vazquez, S. R., Gouripeddi, R., et al. (2026) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-026-03310-7 · Cited by 1
Choudhuri, B. (2026) · Case Reports in Gastroenterology · doi:10.1159/000552414 · Cited by 2
Nguyen, T., Hong, L., & Iso, T. (2026) · Cardiorenal Medicine · doi:10.1159/000552517 · Cited by 1
Recombinant Protein Drugs: A 2025 Update
López‐Laguna, H., Parladé, E., Favaro, M. T. D. P., Palacin, C., Voltà‐Durán, E., Ferrer‐Miralles, N., Corchero, J. L., Rodríguez‐Rodríguez, R., Vázquez, E., Unzueta, U., et al. (2026) · BioDrugs · doi:10.1007/s40259-026-00783-z · Cited by 4
Hundal, J., Chen, J., Russell, K. B., Carfang, L., Bedeau, A. J., Giguère, L., Ouattara, M. M., Sehabi, G., Lebel, S., Shen, S., et al. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517396 · Cited by 1
Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study
Angelopoulos, N., Rizoulis, A. A., Boniakos, A., Fousteris, E., Mentzelopoulou, V., Zianni, D., Livadas, S., & Paparodis, R. D. (2026) · Nutrition · doi:10.1016/j.nut.2026.113286 · Cited by 4
Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights
Laos, E. G. M., Serafica, B., Fontaine-Nicola, A., Zhang, L., Abdelhady, K., Berger, R., Schlottmann, F., Pirzada, A., & Masrur, M. A. (2026) · Clinical Obesity · doi:10.1111/cob.70084 · Cited by 2
Psychosocial Outcomes in Telemedicine and Long‐Acting Incretin‐Specific Behavioral Intervention
Heinberg, L. J., Lee, A. M., Foster, G. D., Zajichek, A., Nadolsky, S., DiVita, A. L., Rotroff, D. M., & Cardel, M. I. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70149 · Cited by 1
An Ounce of Prevention and a Pound of Cardiac Rehabilitation
Reed, J., Mullen, K. A., Small, S. L., Moran, C., Mir, H., Tulloch, H. E., Terada, T., Heshmati, J., Harris, J., Coja, M., et al. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.02.036 · Cited by 2
Pan, S., Weng, C., Sheen, Y., Chen, J., Lin, H., Wang, I., & Chou, C.-C. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101245 · Cited by 2
Lasik, L., & Ukleja-Sokołowska, N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114658 · Cited by 1
Shin, M. H., Jeong, J. W., Ha, S. E., Singh, R., Lee, M. Y., Ro, S., & Yu, T. Y. (2026) · Pharmaceuticals · doi:10.3390/ph19050791 · Cited by 1
Joy, E., & Bonnet, J. P. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261450530 · Cited by 1
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 2
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
Ghosal, S., & Ghosal, A. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100281 · Cited by 2
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.